Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that a Pre-Approval Inspection (PAI) was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals, Inc. (‘InvaGen’), a wholly owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, from 2nd February, 2026 to 9th February, 2026. On conclusion of the inspection, InvaGen has received 2 inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.
The above information is a part of company’s filings submitted to BSE.
